
Ajanta Pharma Ltd. delivered impressive financial results for the September quarter of FY27, with net profit rising 49% to ₹388 crore compared with ₹260.2 crore in the corresponding quarter last year. According to reports from CNBC TV18, the pharmaceutical company's revenue from operations increased 32.5% year-on-year to ₹1,794.2 crore, against ₹1,354 crore in the year-ago period. The strong performance reflects the company's robust operational execution and market positioning. As per NDTV Profit, the company exceeded brokerage estimates by 6.0% and consensus by 12.7%, with the beat primarily driven by strong export performance.
The export segment emerged as the primary growth driver, with export revenue reaching ₹1,278 crore, ahead of estimates by 6.8%. According to NDTV Profit, within exports, Africa significantly outperformed expectations, exceeding estimates by 34.4%, while Asia and the US were below estimates by 1.4% and 4.4%, respectively. The Africa institutional business showed exceptional 259% growth, driven by strong procurement, though this exceptional performance is unlikely to sustain at similar levels in H2. India continued to deliver healthy growth of 16% YoY, supported by strong volumes and new launches, while Africa branded generics grew 41% YoY. The company's high growth branded generics (BGx) market spread across India, Asia and Africa contributed 70% to total revenue in FY26.
At the operating level, Ajanta Pharma demonstrated significant improvement in profitability metrics. As reported by CNBC TV18, the company reported EBITDA of ₹547.6 crore for the quarter, with EBITDA margin expanding to 30.5% from 24.2% in the corresponding period last year. This margin expansion of 630 basis points indicates improved operational efficiency and cost management during the quarter. The latest data shows EBITDA margin expanded to 23.27% from 22.85%, indicating continued operational improvements. Prabhudas Lilladher notes that Q2FY27 EBITDA grew strongly by 47% YoY (₹5.43bn; 30.2% OPM) which was sharply above estimates, aided by higher revenues across branded generic markets.
The company has strengthened its market position through a recent in-licensing agreement with Biocon for marketing semaglutide in 26 countries across RoW markets, which is viewed as a good fit given its strong existing franchise across these markets. Prabhudas Lilladher expects EBITDA/PAT CAGR of 20% over FY26-29E with healthy RoE/RoCE of 25%/31% in FY27E. The brokerage maintains a BUY rating with revised target price of ₹4,250/share (32x Sept 2028E EPS), with FY28E and FY29E EPS stands increased by 3-6%. The company's strong annual free cash flow of ₹8–10bn further supports sustained investments and potential inorganic opportunities, reinforcing medium-term growth visibility.